VivoSeq
Oncology

Colorectal Neoplasm

50

Pipeline Programs

0

Active Trials

26

Companies Involved

Colorectal Neoplasm is a moderately active landscape with 50 programs across 26 companies. The most active players are Nanjing Chia-tai Tianqing Pharmaceutical, Innovent Biologics (Suzhou) Co. Ltd., Tracon Pharmaceuticals Inc.. 23 therapies are approved with 5 more in late-stage development.

Pipeline Metrics

Competitive Density

59/100

Pipeline Velocity

0/100

Mech. Concentration

12/100

Completion Rate

N/A

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

73%

Small molecule

38 of 52 classified programs — the dominant modality here.

27%ALL OTHERSMonoclonal antibody1223%Antibody–drug conjugate12%Protein / enzyme12%

Small molecule leads; the ring shows all 52 classified programs, each share of the total. Modality classified for 100% of 53 pipeline programs.

Trial Status

1

clinical trials

Unknown status1 · 100%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)